In vitro method for diagnosing hepatocellular carcinoma (hcc) in an individual, or for assessing an individual's predisposition to the development of hcc, or for assessing the progression of said disease in an individual, or for determining the stage or severity of said disease. disease in an individual, in vitro method for identifying and evaluating the effectiveness of hcc treatments, use of a gene nucleotide sequence, use of a gene selected from adh, aop2, smp30, nslt, asao, sap genes , pgm, p4h, apoa1, caiii, addhm, oat, oct and combinations thereof, and / or a selected protein from adh proteins, aop2, smp30, nslt, asao, sap, pgm, p4h, apoa1, caiii, addhm, oat, oct and combinations thereof, Method for selection, screening, identification, development and evaluation of the efficacy of compounds in the treatment of hcc, In vitro method to identify a stage prior to the development of hepatocellular carcinoma (hcc) in an ind iv, use of a gene selected from the adh, aop2, smp30, nslt, a

摘要

IN VIT METHOD FOR DIAGNOSING HEPATOCELLULAR CARCINOMA (HCC) IN AN INDIVIDUAL, OR FOR ASSESSING THE INDIVIDUAL'S PREDISPOSITION TO THE DEVELOPMENT OF HCC, OR FOR ASSESSING THE PROGRESS OF THE SUCCESSFUL DEAD, AGAINST THE HEAD OF THE AGE, DISEASE IN AN INDIVIDUAL, IN VITRO METHOD FOR THE IDENTIFICATION AND EVALUATION OF THE EFFICACY OF HCC TREATMENTS, USE OF A NUCLEOTIDE SEQUENCE OF A GENE, USE OF A GENE SELECTED FROM THE GENES ADH, AOP2, SMP3AO, SAPL, ASL, , PGM, P4H, APOAl, FALL, AdDHm, OAT, OCT AND THE COMBINATIONS OF THESE, AND / OR A SELECTED PROTEIN FROM ADH, AOP2, SMP3O, NSLT, ASAO, SAP, PGM, P4H, APOAL, CAIII, AdDHm, OAT, OCT AND THE COMBINATIONS OF THESE, METHOD FOR SELECTING, SEARCHING, IDENTIFYING, DEVELOPING AND EVALUATING THE EFFICACY OF COMPOUNDS IN THE TREATMENT OF HCC, IN VITRO METHOD OF IDENTIFYING A HERITAGE AGAINST THE DETERMINING STAGE IN AN INDIVIDUAL , USE OF A GENE SELECTED AMONG THE GENES ADH, AOP2, SMP3O, NSLT, ASAO, SAP, PGM, AND THE COMBINATIONS OF THESE, AND / OR A PROTEIN SELECTED AMONG THE ADH, AOP2, SMP3O, NSLT, ASAO, SAP, PROTEINS PGM, AND THE COMBINATIONS OF THESE, METHOD FOR SELECTING, SEARCHING, IDENTIFYING, DEVELOPING AND EVALUATING THE EFFICACY OF COMPOUNDS IN TREATING AN STAGE BEFORE THE DEVELOPMENT OF HCC, COMPOSITION, STRUCTURAL EXPERTISE, STRUCTURAL EXPERTISE, COMPOSITION GENES ADH, AOP2, SMP3O, NSLT, ASAO, SAP, PGM, P4H, APOAl, CAIu, AdDHm, OAT AND / OR OCT, OR THE ACTIVITY OF ADH PROTEINS, AOP2, SMP3O, NSLT, ASAO, SAP, PGM, P4H , APOAl, CAIII, AdDHm, OAT AND / OR OCT, USE OF A COMPOUND THAT INTENSIFIES THE EXPRESSION OF THE ADH, AOP2, SMP3O, NSLT, ASAQI SAP and / or PGM GENES, OR THE ACTIVITY OF THE ADH, AOP2, SMP3O, NSLT PROTEINS , ASAO, SAP AND / OR PGM, PRIMER OLIGONUCLEOTIDE PAIR TO SPECIFICALLY AMPLIFY A MRNA OR cDNA FRAGMENT OF A GENE, PROBE, ANTIBODY, SUPPORT SOLID AND KIT Using a proteomic approach, the markers of hepatocellular carcinoma (HCC) in the liver of a knockout mouse (MATiA -! -) were identified for the MATIA gene (deficient in the synthesis of 5-adenosylmethionine). Twenty-seven proteins were detected whose expression is altered in at least 50% of the analyzed tumors. Among them, thirteen proteins were validated in biopsies of patients with HCC of different etiology and seven of them were validated in biopsies of patients with liver cirrhosis, one stage before the development of HCC, which makes it possible to differentiate between previous stages of the disease and even even between different etiologies (viral and alcoholic). The fact that a chart of markers is available can help to define more precisely the changes associated with the development of HCC and, thus, facilitate the prognosis and diagnosis of this disease.